CTOs on the Move

AbbVie Canada

www.abbvie.ca

 
We`re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people`s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today`s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We`re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients` ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.abbvie.ca
  • 8401 Trans-Canada Highway
    Saint-Laurent, QC CAN H4S 1Z1
  • Phone: 514.906.9700

Executives

Name Title Contact Details

Similar Companies

Advanced Pharmacy Concepts

Advanced Pharmacy Concepts is a North Kingstown, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sandoz

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents.

MassMEDIC

The Heart of Healthtech Beats Here. We proudly serve as the voice of the #healthtech industry in New England, representing companies changing the world.

LifeNet Health

LifeNet Health helps save lives, restore health, and give hope to thousands each year.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).